Pedraza Salvador, Puig Josep, Blasco Gerard, Daunis-i-Estadella Josep, Boada Imma, Bardera Anton, Prats Alberto, Castellanos Mar, Serena Joaquin
MRI Center, Institute of Diagnostic Imaging (IDI), Radiology Department, University Hospital Dr. Josep Trueta, Girona, Spain.
Drug News Perspect. 2009 Oct;22(8):481-6.
Ischemic stroke is associated with a high rate of disability and death. Establishing valid biomarkers could help accelerate the approval of promising new therapies for stroke. Whereas many serum biomarkers have been evaluated, possible imaging biomarkers of stroke lack validation. Magnetic resonance imaging (MRI) is a very sensitive technique to study acute stroke and MRI parameters have been established to assess the outcome of acute stroke. This review reassesses the criteria for the validation of MRI biomarkers of acute ischemic stroke (MRI-BAS). Seven criteria were used to review the validity of the main MRI-BAS: vascular status, lesion volume, reversibility on diffusion-weighted imaging, perfusion alteration, penumbra studied with diffusion-perfusion mismatch, clinical-diffusion mismatch, diffusion-angiography mismatch and hemorrhagic transformation. We analyzed the definitions of these biomarkers and the extent to which each fulfills the criteria for validation and found that few MRI-BAS have been fully validated. Further studies should help to improve the validation of current MRI-BAS and develop new biomarkers.
缺血性中风与高致残率和死亡率相关。建立有效的生物标志物有助于加速有前景的中风新疗法的获批。尽管已经评估了许多血清生物标志物,但中风可能的影像学生物标志物仍缺乏验证。磁共振成像(MRI)是研究急性中风的一种非常敏感的技术,并且已经建立了MRI参数来评估急性中风的预后。本综述重新评估了急性缺血性中风MRI生物标志物(MRI-BAS)的验证标准。使用七个标准来审查主要MRI-BAS的有效性:血管状态、病变体积、扩散加权成像上的可逆性、灌注改变、通过扩散-灌注不匹配研究的半暗带、临床-扩散不匹配、扩散-血管造影不匹配和出血性转化。我们分析了这些生物标志物的定义以及每种生物标志物满足验证标准的程度,发现很少有MRI-BAS得到充分验证。进一步的研究应有助于改进当前MRI-BAS的验证并开发新的生物标志物。